The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2021 | Optimizing outcomes with pre- and post-transplant interventions
Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, shares an overview of his talk on the optimization of pre-and post-transplant interventions at EBMT 2021. Allogeneic stem cell transplantation (allo-SCT) remains the only curative approach in many hematological malignancies, however, allo-SCT alone may not be sufficient, and post-transplant consolidation and maintenance may be required. Prof. Mohty discusses how disease-control prior to transplant and post-transplant are key to preventing disease recurrence, highlighting evidence from patients with FLT3-ITD acute myeloid leukemia treated with FLT3 inhibitors post-transplant. This interview took place during the 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2021.
